Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 4Terminated 3

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Recurrence 1Lung Neoplasms 1Lethal Congenital Contracture Syndrome 2 1Fibromatosis, Gingival, 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × patritumab × Clear all
NCT01211483 2021-06-16

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Daiichi Sankyo

Phase 1/2 Completed
222 enrolled 23 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02350712 2018-09-11

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Daiichi Sankyo

Phase 1 Completed
15 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT01957280 2014-05-14

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

Daiichi Sankyo

Phase 1 Completed
17 enrolled
Other solid neoplasm

Solid Tumors

NCT00730470 2010-07-29

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

U3 Pharma GmbH

Phase 1 Completed
60 enrolled

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡